Navigation Links
BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital in Biomarker Research for Personalized Cancer Therapies
Date:11/16/2011

MADRID, Nov. 16, 2011 /PRNewswire/ -- The BBVA Foundation announced an agreement to underwrite a joint effort between Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital to search for personalized cancer therapies through biomarker research.

The BBVA Foundation Tumor Biomarkers Research Program will provide 2.5 million euros over the next five years to fund the collaborative efforts of MGH and VHIO.  MGH has also committed to match up to 1.25 million euros of the BBVA Foundation contribution.  Funding for the research may be increased according to economic circumstances and as need arises.

"We are grateful that the BBVA Foundation is not only maintaining but boosting its support for this program, along with its broader commitment to research in general, and cancer research in particular, at a time of economic difficulties," said Josep Baselga, chief of hematology/oncology at MGH.

BBVA Foundation President Francisco Gonzalez concurred, adding: "Spain cannot afford to slip behind in an area where it has already attained a position of some prominence, and where research results can drive tangible improvements in the diagnostic and therapeutic options available to patients."  

BBVA Foundation President and BBVA CEO Francisco Gonzalez, Josep Baselga, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center, and Andres de Kelety, managing director at the Vall d'Hebron Institute of Oncology signed the agreement creating the program Monday in Barcelona. Also attending the event was the BBVA Foundation Director Rafael Pardo.

Biomarkers are biological characteristics of malignant cells that are measurable in tumor tissue and, at times, in blood. Biomarkers can measure alterations of the genome, of the proteins encoded by the genome and at times enzymes or metabolites. The information they give can be prognostic – how the disease is likely to evolve – or predictive – how it may respond to a given treatment. Studies in this case will initially center on colorectal, breast and lung cancer, with likely expansion into melanomas, lymphomas, and prostate cancer.

For more information on the BBVA Foundation, please visit http://www.fbbva.es/TLFU/tlfu/ing/home/index.jsp.


'/>"/>
SOURCE BBVA Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
2. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
3. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
4. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
5. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. GBS/CIDP Foundation to Hold 10th International Symposium
8. Mirixa Corporation and the APhA Foundation Form Partnership
9. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
10. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
11. Canary Foundations Dr. Sanjiv Sam Gambhir Elected to the National Academies Institute of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
Breaking Biology News(10 mins):